leflunomide has been researched along with Arthritis, Spinal in 3 studies
Leflunomide: An isoxazole derivative that inhibits dihydroorotate dehydrogenase, the fourth enzyme in the pyrimidine biosynthetic pathway. It is used an immunosuppressive agent in the treatment of RHEUMATOID ARTHRITIS and PSORIATIC ARTHRITIS.
leflunomide : A monocarboxylic acid amide obtained by formal condensation of the carboxy group of 5-methyl-1,2-oxazole-4-carboxylic acid with the anilino group of 4-(trifluoromethyl)aniline. The prodrug of teriflunomide.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (33.33) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 1 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Marques, CDL | 3 |
| Ribeiro, SLE | 3 |
| Albuquerque, CP | 3 |
| de Sousa Studart, SA | 3 |
| Ranzolin, A | 3 |
| de Andrade, NPB | 3 |
| Dantas, AT | 3 |
| Mota, GD | 3 |
| Resende, GG | 3 |
| Marinho, AO | 3 |
| Angelieri, D | 3 |
| Andrade, D | 3 |
| Ribeiro, FM | 3 |
| Omura, F | 3 |
| Silva, NA | 3 |
| Rocha Junior, L | 3 |
| Brito, DE | 3 |
| Fernandino, DC | 3 |
| Yazbek, MA | 3 |
| Souza, MPG | 3 |
| Ximenes, AC | 3 |
| Martins, ASS | 3 |
| Castro, GRW | 3 |
| Oliveira, LC | 3 |
| Freitas, ABSB | 3 |
| Kakehasi, AM | 3 |
| Gomides, APM | 3 |
| Reis Neto, ET | 3 |
| Pileggi, GS | 3 |
| Ferreira, GA | 3 |
| Mota, LMH | 3 |
| Xavier, RM | 3 |
| de Medeiros Pinheiro, M | 3 |
| Krüger, K | 1 |
| Sieper, J | 2 |
| Braun, J | 1 |
1 review available for leflunomide and Arthritis, Spinal
| Article | Year |
|---|---|
[Off-label therapy of rheumatoid arthritis and spondyloarthritis].
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Biological Products; Dose-Response Relationship, Drug; | 2012 |
2 other studies available for leflunomide and Arthritis, Spinal
| Article | Year |
|---|---|
COVID-19 was not associated or trigger disease activity in spondylarthritis patients: ReumaCoV-Brasil cross-sectional data.
Topics: Arthritis, Psoriatic; Brazil; COVID-19; Cross-Sectional Studies; Humans; Leflunomide; Middle Aged; P | 2022 |
COVID-19 was not associated or trigger disease activity in spondylarthritis patients: ReumaCoV-Brasil cross-sectional data.
Topics: Arthritis, Psoriatic; Brazil; COVID-19; Cross-Sectional Studies; Humans; Leflunomide; Middle Aged; P | 2022 |
COVID-19 was not associated or trigger disease activity in spondylarthritis patients: ReumaCoV-Brasil cross-sectional data.
Topics: Arthritis, Psoriatic; Brazil; COVID-19; Cross-Sectional Studies; Humans; Leflunomide; Middle Aged; P | 2022 |
COVID-19 was not associated or trigger disease activity in spondylarthritis patients: ReumaCoV-Brasil cross-sectional data.
Topics: Arthritis, Psoriatic; Brazil; COVID-19; Cross-Sectional Studies; Humans; Leflunomide; Middle Aged; P | 2022 |
COVID-19 was not associated or trigger disease activity in spondylarthritis patients: ReumaCoV-Brasil cross-sectional data.
Topics: Arthritis, Psoriatic; Brazil; COVID-19; Cross-Sectional Studies; Humans; Leflunomide; Middle Aged; P | 2022 |
COVID-19 was not associated or trigger disease activity in spondylarthritis patients: ReumaCoV-Brasil cross-sectional data.
Topics: Arthritis, Psoriatic; Brazil; COVID-19; Cross-Sectional Studies; Humans; Leflunomide; Middle Aged; P | 2022 |
COVID-19 was not associated or trigger disease activity in spondylarthritis patients: ReumaCoV-Brasil cross-sectional data.
Topics: Arthritis, Psoriatic; Brazil; COVID-19; Cross-Sectional Studies; Humans; Leflunomide; Middle Aged; P | 2022 |
COVID-19 was not associated or trigger disease activity in spondylarthritis patients: ReumaCoV-Brasil cross-sectional data.
Topics: Arthritis, Psoriatic; Brazil; COVID-19; Cross-Sectional Studies; Humans; Leflunomide; Middle Aged; P | 2022 |
COVID-19 was not associated or trigger disease activity in spondylarthritis patients: ReumaCoV-Brasil cross-sectional data.
Topics: Arthritis, Psoriatic; Brazil; COVID-19; Cross-Sectional Studies; Humans; Leflunomide; Middle Aged; P | 2022 |
[Spondylarthritides].
Topics: Adalimumab; Adult; Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Monoclonal; Antibodies, Mono | 2006 |